PP_1170x120_10-25-21

Clinical Research Institute of Southern Oregon

Sunovion ships Seebri Neohaler to pharmacies

Sunovion ships Seebri Neohaler to pharmacies

MARLBOROUGH, Mass. — Sunovion Pharmaceuticals Inc. has released Seebri Neohaler Inhalation Powder (glycopyrrolate 15.6 mcg), a treatment for chronic obstructive pulmonary disease (COPD), to U.S. pharmacies. Sunovion said Thursday that it entered into an exclusive license agreement with Novartis for the U.S. commercialization rights to Seebri Neohaler, as well as Utibron Neohaler and Arcapta Neohaler, in

Adheris Health